EA200300125A1 - Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича - Google Patents

Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича

Info

Publication number
EA200300125A1
EA200300125A1 EA200300125A EA200300125A EA200300125A1 EA 200300125 A1 EA200300125 A1 EA 200300125A1 EA 200300125 A EA200300125 A EA 200300125A EA 200300125 A EA200300125 A EA 200300125A EA 200300125 A1 EA200300125 A1 EA 200300125A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cabergoline
treatment
application
supranuklear
paralich
Prior art date
Application number
EA200300125A
Other languages
English (en)
Inventor
Балтасар Гомес-Мансилья
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of EA200300125A1 publication Critical patent/EA200300125A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Настоящее изобретение раскрывает новое применение и способы лечения с привлечением каберголина. В настоящем документе раскрывается применение каберголина для лечения ПСП и ПСА.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300125A 1998-05-15 1999-05-07 Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича EA200300125A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8561998P 1998-05-15 1998-05-15
US8794398P 1998-06-04 1998-06-04

Publications (1)

Publication Number Publication Date
EA200300125A1 true EA200300125A1 (ru) 2003-06-26

Family

ID=26772918

Family Applications (4)

Application Number Title Priority Date Filing Date
EA200200955A EA200200955A1 (ru) 1998-05-15 1999-05-07 Каберголин и прамипексол для лечения заболевания цнс, особенно болезни паркинсона
EA200001192A EA004474B1 (ru) 1998-05-15 1999-05-07 Комбинированное лечение заболевания цнс, особенно болезни паркинсона, путём совместного введения каберголина и прамипексола
EA200300125A EA200300125A1 (ru) 1998-05-15 1999-05-07 Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича
EA200300124A EA200300124A1 (ru) 1998-05-15 1999-05-07 Применение прамипексола для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA200200955A EA200200955A1 (ru) 1998-05-15 1999-05-07 Каберголин и прамипексол для лечения заболевания цнс, особенно болезни паркинсона
EA200001192A EA004474B1 (ru) 1998-05-15 1999-05-07 Комбинированное лечение заболевания цнс, особенно болезни паркинсона, путём совместного введения каберголина и прамипексола

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200300124A EA200300124A1 (ru) 1998-05-15 1999-05-07 Применение прамипексола для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича

Country Status (22)

Country Link
US (1) US6503920B1 (ru)
EP (1) EP1076559B1 (ru)
JP (1) JP2002515425A (ru)
KR (3) KR20060056417A (ru)
CN (1) CN1301159A (ru)
AT (1) ATE310517T1 (ru)
AU (1) AU748629B2 (ru)
BR (1) BR9909917A (ru)
CA (1) CA2327299A1 (ru)
DE (1) DE69928521T2 (ru)
DK (1) DK1076559T3 (ru)
EA (4) EA200200955A1 (ru)
ES (1) ES2251191T3 (ru)
HU (1) HUP0101803A3 (ru)
IL (1) IL139682A0 (ru)
NO (1) NO20005757D0 (ru)
NZ (2) NZ508184A (ru)
PL (1) PL344574A1 (ru)
SG (1) SG121745A1 (ru)
SK (1) SK16272000A3 (ru)
TR (1) TR200003356T2 (ru)
WO (1) WO1999059563A2 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
GB0221513D0 (en) 2002-09-17 2002-10-23 Generics Uk Ltd Novel compounds and processes
CN101005830B (zh) 2004-08-13 2010-09-29 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂、其制备方法及用途
NZ553645A (en) 2004-08-13 2010-09-30 Boehringer Ingelheim Int Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
JP2009526021A (ja) * 2006-02-10 2009-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 放出を加減した製剤
PL232974B1 (pl) * 2015-12-09 2019-08-30 Ofta Spolka Z Ograniczona Odpowiedzialnoscia Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
WO1995005176A1 (en) * 1993-08-18 1995-02-23 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
FR2728374A1 (fr) * 1994-12-15 1996-06-21 Aerospatiale Procede et dispositif pour fournir une information, alerte ou alarme pour un aeronef a proximite du sol
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent

Also Published As

Publication number Publication date
CN1301159A (zh) 2001-06-27
SG121745A1 (en) 2006-05-26
KR20010043612A (ko) 2001-05-25
EA200200955A1 (ru) 2002-12-26
EP1076559B1 (en) 2005-11-23
NO20005757L (no) 2000-11-14
EA200001192A1 (ru) 2001-04-23
AU3741999A (en) 1999-12-06
EP1076559A2 (en) 2001-02-21
US6503920B1 (en) 2003-01-07
NO20005757D0 (no) 2000-11-14
EA200300124A1 (ru) 2003-10-30
KR20060056416A (ko) 2006-05-24
BR9909917A (pt) 2000-12-26
SK16272000A3 (sk) 2001-05-10
WO1999059563A3 (en) 2000-04-13
ATE310517T1 (de) 2005-12-15
KR20060056417A (ko) 2006-05-24
WO1999059563A2 (en) 1999-11-25
DE69928521T2 (de) 2006-07-27
JP2002515425A (ja) 2002-05-28
HUP0101803A2 (hu) 2002-03-28
HUP0101803A3 (en) 2002-10-28
IL139682A0 (en) 2002-02-10
ES2251191T3 (es) 2006-04-16
PL344574A1 (en) 2001-11-05
TR200003356T2 (tr) 2001-03-21
CA2327299A1 (en) 1999-11-25
DK1076559T3 (da) 2006-01-16
EA004474B1 (ru) 2004-04-29
NZ526071A (en) 2004-11-26
DE69928521D1 (de) 2005-12-29
NZ508184A (en) 2004-01-30
AU748629B2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
EA199900324A1 (ru) Комбинированная терапия для лечения психозов
EA199900325A1 (ru) Форма d дигидрата оланзапина
EA200400284A1 (ru) Антинеопластические комбинации
EA200300125A1 (ru) Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича
EA200100688A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
DE69728585D1 (de) Mittel gegen Juckreiz
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
EA200000381A1 (ru) Препарат 2-метил-тиено-бензодиазепина
MY136097A (en) Methods for treating osteoarthritis using an estrogen agonist/antagonist
WO2002014925A3 (en) Lamp structure, having elliptical reflectors, for uniformly irradiating surfaces of optical fiber and method of use thereof
DE69812440D1 (de) Gasenladenungsröhre
EA199900620A1 (ru) Фталазиноны
EA200300429A1 (ru) Способ получения порошковых композиций
EA199900362A1 (ru) Новые соединения, полезные для использования в качестве нейрозащитных средств
FI972066A (fi) Uusi kasvainten suppressorigeeni HIC-1
EA199900326A1 (ru) Промежуточные соединения и способ получения оланзапина
IL125738A0 (en) Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
DE69732762D1 (de) Indanderivate für antipsychotische mittel
IL146701A0 (en) Therapy for andropause using estrogen agonists/antagonists and testosterone
BR0109052A (pt) Método de tratamento de lixo sólido com uma fração orgânica
EA199800753A1 (ru) Бензотиофены, составы их содержащие и способы с их использованием
EA200200798A1 (ru) Кальцилитические соединения
EA200000561A1 (ru) Триазиновые соединения для лечения расстройств цнс
EA199900241A1 (ru) ЗАМЕЩЕННЫЕ 1,2,3,4-ТЕТРАГИДРО-2-ДИБЕНЗОФУРАНАМИНЫ И 2-АМИНОЦИКЛОГЕПТА [b] БЕНЗОФУРАНЫ
EA200300978A1 (ru) Ингибирование поглощения моноамина